login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
C4 THERAPEUTICS INC (CCCC) Stock News
USA
- NASDAQ:CCCC -
US12529R1077
-
Common Stock
2.46
USD
-0.08 (-3.15%)
Last: 10/21/2025, 4:22:20 PM
2.46
USD
0 (0%)
After Hours:
10/21/2025, 4:22:20 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CCCC Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
5 days ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
a month ago - By: Benzinga
Forecasting The Future: 4 Analyst Projections For C4 Therapeutics
3 months ago - By: The Motley Fool
CCCC Revenue Drops 46%
18 days ago - By: Benzinga
- Mentions:
DBVT
ACIU
CLPT
OVID
...
12 Health Care Stocks Moving In Friday's Pre-Market Session
20 days ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
20 days ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
a month ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
a month ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
a month ago - By: The Motley Fool
Why C4 Therapeutics Stock Crushed the Market on Monday
2 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
2 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
2 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
2 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
3 months ago - By: Zacks Investment Research
- Mentions:
DARE
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
3 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
3 months ago - By: Zacks Investment Research
- Mentions:
OCGN
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
6 months ago - By: Zacks Investment Research
- Mentions:
NTLA
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
6 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
6 months ago - By: Zacks Investment Research
- Mentions:
SAGE
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
8 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
8 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
8 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics to Participate in Upcoming March Investor Conferences
9 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
9 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
10 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
10 months ago - By: C4 Therapeutics, Inc.
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Please enable JavaScript to continue using this application.